Kelonia Therapeutics

Kelonia’s work advancing #invivo #CARTcell therapies using our iGPS® technology was recently featured in a segment of Advancements with Ted Danson.    Watch the segment below to hear our CEO Kevin Friedman, Director of Preclinical Research Emily Thompson Beura, PhD, Board Member and Massachusetts Institute of Technology Professor, Michael Birnbaum, and Noopur Raje, Director of the Center for #MultipleMyeloma at MGH, speak about our pioneering technology and its exciting possibilities for the future. View the full episode here: https://lnkd.in/g_3U5-hF.  #KeloniaOnAdvancements

Here at Kelonia Therapeutics, we’re trailblazers striving to revolutionize in vivo gene delivery. We're not just a team, we're dreamers on a mission to bring the promise of #CellandGeneTherapy to every patient in need. Check out the newest opening on our Research team: Principal Scientist, Preclinical Research!   Click here to learn more about all of our open positions: https://lnkd.in/gE8PfGbt   #hiring #boston

We had a blast last week celebrating the opening of our new office and lab space with our family and friends at our Open House and Family Day!    We loved showing off our new space to our industry colleagues and key business partners and enjoying time with the important people in our team’s lives. A special thank you to our landlords at Beacon Capital Partners and all our vendors for their help getting us settled into our new space at Southline Boston!

Last month, we had the privilege of hosting Dr. Kristen Hege, Kelonia board member and trailblazer in the field of cell therapy, for an inspiring leadership talk! Dr. Hege shared profound insights from her journey hiking the Pacific Coast Trail, drawing compelling parallels to her pioneering work in CAR T-cell therapies. Her reflections on leadership, perseverance, and embracing challenges left a lasting impact on all who attended and continues to resonate with our team as we continue our work advancing our own lead in vivo CAR T program to the clinic.

We had a blast partnering with teammates from Special Olympics Massachusetts at last week’s Bio-Ball 2024 fundraiser and basketball tournament. We came together to #playunified and raise money for a great cause alongside our biotech industry peers. Team Kelonia proudly raised $16,378 for Special Olympics Massachusetts, putting us in 3rd place in the fundraising challenge, and securing our chance to play on the parquet floor at TD Garden with our teammates from Special Olympics Lynn & Haverill!     Learn more about how you can support: https://lnkd.in/gBB2QkVP.  #ChooseToInclude #PlayUnified 

Our Vice President, Strategy and Business Development, Bharat Reddy, is attending Biotechnology Innovation Organization’s #BIO2024. Connect with us in sunny San Diego, to learn more about our iGPS® platform exciting work advancing #invivo CAR-T therapies for cancer: https://lnkd.in/eEDtKaAK.

We’ll be participating in next month’s #BioBall tournament alongside our #biotech and #lifescience peers to fundraise for the Special Olympics Massachusetts. This event is dedicated to supporting over 19,000 #SpecialOlympics athletes and their families.  Join us in fostering inclusion and support this great mission! Donate on behalf of #TeamKelonia today: https://lnkd.in/g97kkWVd #BioBall24

We pride ourselves on our unwavering dedication to our people-first mission and the collective achievements made in our pursuit of transformative therapeutics.    Our team is shaping the future of #geneticmedicines as we know it. Discover a culture where innovation meets purpose at Kelonia: https://lnkd.in/gVjmXDJN

We will be presenting preclinical data from our lead #InVivo #CART candidate, KLN-1010, at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting and the Protein Engineering Summit (PEGS) Boston Summit 2024. Learn more: https://lnkd.in/gY4Fm5i4 #MultipleMyeloma #ASGCT24 #PEGSummit

Our iGPS® technology utilizes advanced lentiviral vectors to achieve precise and efficient #genedelivery in patients. Our cell and gene therapies would have the potential to efficiently treat a wide range of serious and chronic diseases without requiring pretreatment chemotherapies, lengthy manufacturing or long delivery timelines often associated with existing therapies.   Learn more about our platform: https://lnkd.in/g8kWVyMV